Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 27 September 2022 Invitation to the Extraordinary Shareholders’ Meeting Regulated information 26 September 2022 Biocartis Announces Launch of Amendment Process and Exchange Offer for its Existing Convertible Bonds Regulated information 6 September 2022 Disclosure of outstanding voting securities Regulated information 1 September 2022 BIOCARTIS ANNOUNCES H1 2022 RESULTS Regulated information 1 September 2022 Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients Non-regulated information 1 September 2022 Biocartis Announces Entry into Comprehensive Recapitalization Arrangements to Strengthen Cash Position and Support Growth Inside information Regulated information 25 August 2022 Biocartis Announces 2022 Half-Year Results on 1 September 2022 Regulated information 24 August 2022 Biocartis Obtains ISO 27001 Certification for Information Security Management Non-regulated information 22 June 2022 Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso® Non-regulated information 20 June 2022 Biocartis Announces Launch of its Rapid CE-marked IVD Idylla™ GeneFusion Panel for Fast Treatment Decisions in Lung Cancer Non-regulated information Pagination First page « First Previous page ‹‹ … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page ›› Last page Last »